Committees

Committee members play a critical role in providing FDLI with subject-matter and editorial advisory expertise.

2024 Committees

Program Committees

The Advertising and Promotion for Medical Products Planning Committee supports FDLI staff in planning this event, which typically takes place in October. Responsibilities include identifying key issues and hot topics, evaluating conference submissions, recommending and recruiting speakers (including keynotes), and promoting the program to colleagues.

  • Lauren Caroline Tadros Potter (Staff Liaison), FDLI
  • Dale Cooke (Co-Chair), PhillyCooke Consulting
  • Jae Kim (Co-Chair), DLA Piper LLP (US)
  • Katie Bond, Keller and Heckman LLP
  • Hannah R. Bornstein, Nixon Peabody LLP
  • Dominick P. DiSabatino, Sheppard Mullin Richter & Hampton LLP
  • Mark Gardner, Gardner Law, PLLC
  • Abraham Gitterman, Arnold & Porter LLP
  • Alan G. Minsk, Arnall Golden Gregory LLP
  • Anisa Mohanty, DLA Piper
  • Devaki Patel, Alston & Bird LLP
  • Nancy E. Taylor, Greenberg Traurig, LLP
  • Sara Wexler Koblitz, Hyman, Phelps & McNamara, PC
  • Heta Zaveri, Opus Regulatory, Inc.

Annual Conference Planning Committee helps plan and implement FDLI’s Annual Conference, the premier event of the food and drug law community. This conference is typically held in the spring.

  • Paige Samson (Staff Liaison), FDLI
  • Stacy Cline Amin(Co-Chair), Oracle  
  • Lowell Zeta (Co-Chair), Hogan Lovells US LLP
  • Laura Akowuah, FDA—CFSAN
  • Kalah Auchincloss, ELIQUENT Life Sciences
  • Jennifer Bragg, Latham & Watkins LLP
  • Shelby Buettner, Becton Dickinson (BD)
  • Andrea Ferrenz, Campbell Soup Company
  • Lewis Grossman, American University
  • Dorothy Hatsukami, University of Minnesota
  • Jeremiah Kelly, Venable LLP
  • Winston Kirton, BakerHostetler
  • Paige Magness, Altria Client Services LLC
  • Sharon Mayl, DLA Piper LLP (US)
  • Rachael Pontikes, Reed Smith LLP
  • Mimi Riley, University of Virginia
  • Schevon Salmon, Otsuka America Pharmaceutical, Inc.
  • Sarah Sorscher, Center for Science in the Public Interest
  • Sarah Stec, Johnson & Johnson
  • Stuart TenHoor, Stuart TenHoor Legal Search
  • Rachel Turow, Skadden, Arps, Slate, Meagher & Flom LLP
  • Jennifer Zachary, Merck & Co., Inc.
  • Jessica Zeller, Edwards Lifesciences LLC

The California Programs Committee supports FDLI staff in identifying and assessing programming opportunities in California, which may occur throughout the year in the form of a webinar, half-day program, or conference. Responsibilities include identifying key issues and hot topics, developing conference agendas, recommending and recruiting speakers, and promoting programs to colleagues.

  • Khara Minter (Staff Liaison), FDLI
  • Sophia Castillo, Keller and Heckman LLP
  • Michelle Davalos, Edwards Lifesciences LLC
  • Janet L. Michener Whipple, ELIQUENT Life Sciences
  • Kiera Murphy, Latham & Watkins LLP
  • Alexander J. Varond, Goodwin Procter LLP

The Digital Health Committee supports FDLI staff in planning and implementing the Digital Health Conference, taking place in the first quarter of the year. Responsibilities include identifying key issues and hot topics, developing the conference agenda, recommending and recruiting speakers (including keynotes), and promoting the conference to colleagues.

  • Nicholas Benetatos, Exponent, Inc.
  • M. Jason Brooke, Brooke & Associates
  • Charlene Cho, Johnson & Johnson
  • Kellie B. Combs, Ropes & Gray LLP
  • Mahnu Davar, Arnold & Porter LLP
  • James Fraser, Thompson Hine LLP
  • Nidhi Gani, Archimedes Center for Medical Device Security, Northeastern University
  • Carmine Jabri, Emma International
  • Jeremiah Kelly, Venable LLP
  • Marian J. Lee, McKesson Corporation
  • Elizabeth Richards, Latham & Watkins LLP
  • Cassie Scherer, Medtronic
  • Sara Shanti, Sheppard Mullin Richter & Hampton LLP
  • Lance L. Shea, Baker Hostetler
  • Eva Temkin, King & Spalding LLP
  • Stuart TenHoor, Stuart TenHoor Legal Search

The Enforcement, Litigation, and Compliance Conference Planning Committee supports FDLI staff in planning this event, which typically takes place in early to mid-December.  Responsibilities include identifying key issues and hot topics, evaluating conference submissions, recommending and recruiting speakers (including keynotes), and promoting the program to colleagues.

  • Khara Minter (Staff Liaison), FDLI
  • Maya P. Florence (Chair), Skadden, Arps, Slate, Meagher & Flom LLP
  • Kelly Bonner, Duane Morris LLP
  • Cathy L. Burgess, Alston & Bird LLP
  • Andrea Chamblee, George Washington University
  • John Claud, Hyman, Phelps & McNamara, PC
  • Aaron Danzig, Arnall Golden Gregory LLP
  • Lynne Ensor, Parexel International Corporation
  • James C. Fraser, Thompson Hine LLP
  • Mark Carlisle Levy, Eckert Seamans Cherin & Mellott, LLC
  • Perham Gorji, DLA Piper LLP (US)
  • Monica Groat, Latham & Watkins LLP
  • Steven A. Johnson, FDA Counsels
  • Peter V. Lindsay, Paul Hastings, LLP
  • Tim Lombardo, EAS Consulting Group
  • David Lonza, NSF International
  • Fred Medick, Genentech, Inc.
  • Anne K. Miller, Medtronic
  • Theodora McCormick, Epstein Becker & Green, PC
  • Clint Narver, McGuireWoods LLP
  • Sonia W. Nath, Cooley LLP
  • Suzan Onel, Kleinfeld, Kaplan & Becker, LLP
  • Teresa Park, Covington & Burling LLP
  • Shannon M. Singleton, FDA – OCC
  • George Toscano, Toscano Consulting Group (TCG)
  • Beth P. Weinman, Ropes & Gray LLP

The FDLI at the Forefront Committee supports FDLI staff on identifying and assessing programing opportunities related to important developments and emerging issues for all FDA-regulated products, with particular emphasis on food, drugs, biologics, and devices. These programs may occur throughout the year and will typically be in the form of a webinar, but also includes half-day programs and conferences. Responsibilities include identifying key issues and hot topics, advising on program format, evaluating webinar proposals, recommending and recruiting speakers, and promoting programs to colleagues.

  • Khara Minter (Staff Liaison), FDLI
  • Paige Samson (Staff Liaison), FDLI
  • Stephanie Agu, Hogan Lovells US LLP
  • Lisa El-Shall, EAS Consulting Group
  • Mark Hendrickson, Leavitt Partners, LLC
  • Michael H. Hinckle, K&L Gates LLP
  • Eileen McMahon, Torys LLP
  • Karla L. Palmer, Hyman, Phelps & McNamara, PC
  • Lee Rosebush, BakerHostetler
  • Ronald Y. Rothstein, Winston & Strawn LLP
  • R. Trent Taylor, McGuireWoods LLP
  • Anne K. Walsh, Hyman, Phelps & McNamara, PC

The Food Advertising, Labeling, and Litigation Conference Planning Committee supports FDLI staff in planning this event, which typically takes place in late September. Responsibilities include identifying key issues and hot topics, evaluating conference submissions, recommending and recruiting speakers (including keynotes), and promoting the program to colleagues.

  • Paige Samson (Staff Liaison), FDLI
  • Benjamin P. Abel, Faegre Drinker Biddle & Reath LLP
  • Matthew G. Ball, K&L Gates LLP
  • Susan M. Bond, Kerry, Inc.
  • Veronica Colas, Hogan Lovells US LLP
  • Sam Dietle, Nestle USA, Inc.
  • Stefanie Jill Fogel, DLA Piper LLP
  • Dale Joseph Giali, King & Spalding LLP
  • Jason W. Gordon, Reed Smith LLP
  • Maia Kats, Just Food Law PLLC
  • Abby Meyer, Sheppard, Mullin, Richter & Hampton LLP
  • Shawn Obi, Winston & Strawn LLP
  • Evangelia C. Pelonis, Keller and Heckman LLP
  • Robert Roos, Associated British Foods plc
  • Amaru Sanchez, Wiley LLP
  • Randal M. Shaheen, BakerHostetler

The Food and Dietary Supplement Safety and Regulation Conference Planning Committee supports FDLI staff in planning this event, which typically takes place in late March or early April. Responsibilities include identifying key issues and hot topics, evaluating conference submissions, recommending and recruiting speakers (including keynotes), and promoting the program to colleagues.

  • Steven Leslie (Staff Liason), FDLI
  • Deepti Kulkarni (Chair), Covington & Burling LLP
  • Andrea Bruce, Hogan Lovells US LLP
  • Laura Dias, Roquette America, Inc.
  • Kris DeAngelo, Michigan State University
  • Robert Durkin, Arnall Golden Gregory LLP
  • Andrea G. Ferrenz, Campbell Soup Company
  • Ernest Fung, Cardno ChemRisk
  • Phyllis Marquitz
  • Lisa Navarro, Ramboll US
  • Omar Oyarzabal, EAS Consulting Group
  • Stuart M. Pape, Polsinelli PC
  • Laura Rich, Venable LLP
  • Christopher Van Gundy, Sheppard Mullin Richter & Hampton LLP
  • Jack Wenik, Epstein Becker & Green, PC

The New to FDA Law and Regulation Planning Committee supports FDLI staff in developing programming for those new to FDA regulated fields (generally within the first seven years). Programming covers a wide range of topics, including recent regulatory developments, career building, and interacting with government agencies, plus networking opportunities for in-person events. Responsibilities include identifying key issues and hot topics, developing in-person and virtual programs, recommending and recruiting speakers, and promoting programs to colleagues.

  • Kelsey Kerr (Staff Liaison), FDLI
  • Jana Caracciolo Perez, Amin Wasserman Gurani
  • Kathryn Culver, Amgen Inc.
  • Jennifer A. Davidson, Kleinfeld, Kaplan & Becker, LLP
  • Laura S. Dona, Arnall Golden Gregory LLP
  • Daniela Drago, NDA Partners LLC
  • Yetunde Fadahunsi, Hogan Lovells US LLP
  • Jaclyn Fonteyne, Sidley Austin LLP
  • Colleen M. Heisey, Jones Day
  • Coleen Hill, Duane Morris LLP
  • Laurie Lenkel, FDA – OC
  • Michael Jordan, Troutman Pepper Hamilton Sanders LLP
  • Jeannie Mancheno, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
  • Rihana Miller, FDA – CDER
  • Kara Schoonover, Foley & Lardner LLP
  • Kelsey Tavares, DLA Piper LLP (US)
  • Rebecca Williams, Ropes & Gray LLP
  • Philip Won, Alston and Bird

The Patient Organization Engagement Committee supports FDLI staff in planning its training course that assists patient organizations in understanding FDA regulations and interacting with the agency. This training course is virtual and typically takes place in February. Responsibilities include identifying key issues and hot topics, developing the agenda, recommending and recruiting speakers, and identifying patient organization partners.

  • Kelsey Kerr (Staff Liaison), FDLI
  • Mitchell Berger, HHS
  • Trisha Devlin, Eli Lilly and Company
  • Devaveena Dey, FDA – CBER
  • Ryan Matthew Hohman, Friends of Cancer Research
  • Barbara Jones-Binns, Alston & Bird LLP
  • Susan S. Lee, Goodwin Procter LLP
  • Elizabeth Mulkey, Goodwin Procter LLP
  • Natalie Oehlers, Buchanan Ingersoll & Rooney PC
  • Amirala Pasha, Mayo Clinic
  • Cara Tenenbaum, Strathmore Health Strategy
  • James Valentine, Hyman, Phelps & McNamara, PC
  • David R. Zook, Faegre Drinker Biddle & Reath LLP
  • Kemi Asante, FDA
  • Kenita Barrow, Otsuka America Pharmaceutical, Inc.
  • Jennifer Bragg, Latham & Watkins LLP
  • Nimi Chhina, BioMarin Pharmaceutical Inc.
  • Carla Cartwright, Johnson & Johnson
  • Sandy Kalter, Medtronic
  • Daniel A. Kracov, Arnold & Porter LLP
  • Deepti Kulkarni, Covington & Burling LLP
  • Marian Lee, McKesson Corporation 
  • Erika Lietzan, U. of Missouri-Columbia School of Law
  • Cynthia Meyer, Kleinfeld, Kaplan & Becker LLP
  • Meredith Olearchik, Campbell Soup Company
  • Peter Pitts, Center for Medicine in the Public Interest
  • Bob Rhoades, ELIQUENT Life Sciences
  • Alex Varond, Goodwin Procter LLP
  • Anne Walsh, Hyman, Phelps & McNamara, PC

Publications Committees

The Austern Writing Awards Committee contributes to fostering the next generation of professionals in the food and drug law field by judging submissions from JD students. Papers to be judged cover all areas of law affecting FDA-regulated industries. The judging period takes place from June through October, after which the committee meets virtually to discuss and determine the winners of the competition.

  • Paige Samson (Staff Liaison), FDLI
  • Jessica DeLalio, Ropes & Gray LLP
  • Sophia Gaulkin, Hyman, Phelps & McNamara, PC
  • Jennifer Kang, Otsuka America Pharmaceutical, Inc.
  • Matthew Piscitelli, Foley Hoag LLP
  • Jennifer Stonecipher Hill, Shook, Hardy & Bacon LLP

The Food and Drug Law Journal Editorial Advisory Board (FDLJ EAB) reviews and evaluates submitted articles, providing substantive feedback in a blinded peer review process for the scholarly legal journal. The articles to be reviewed include analyses of federal legislation, regulations, court decisions, and public policies affected industries regulated by FDA and related agencies and authorities. Members of the FDLJ EAB may also participate in planning the annual Food and Drug Law Journal Symposium, including identifying the theme of the year’s program and recommending moderators and discussants.

  • Paige Samson (Staff Liaison), FDLI
  • Meryl E. Bartlett, Latham & Watkins LLP
  • Laurie J. Beyranevand, Vermont Law and Graduate School
  • James A. Boiani, Epstein Becker & Green, PC
  • Brigid Bondoc, Morrison & Foerster LLP.
  • Nathan A. Brown, Akin Gump Strauss Hauer & Feld LLP
  • Michelle Divelbiss, Covington & Burling LLP
  • Bridget C.E. Dooling, The Ohio State University Moritz College of Law
  • Jamie W. Gamerman, FDA – CDER
  • Peter Barton Hutt, Covington & Burling LLP
  • William M. Janssen, Charleston School of Law
  • John F. Johnson III, Shook, Hardy & Bacon LLP
  • Hannah Leibson, Arnold & Porter LLP
  • Geoffrey M. Levitt, argenx
  • Markham C. Luke, FDA – CDER
  • Catherine A. Melfi, Omeros Corporation
  • Cynthia L. Meyer, Kleinfeld, Kaplan & Becker, LLP
  • Adam Muchmore, Penn State Law
  • Daniel Orr, Wilson Sonsini Goodrich & Rosati
  • Somnath Pal, St. John’s University College of Pharmacy
  • Tyler M. Scandalios, Arnold & Porter LLP
  • Shy Shorer, NIH, NCI, CCR
  • David Simon, Northeastern University School of Law
  • Eric Solowey, Parexel International Corporation
  • Emily Spiegel, Vermont Law and Graduate School
  • Tommy Tobin, Perkins Coie LLP 
  • Mark Tobolowsky, Hyman, Phelps & McNamara, PC
  • Andrew Wasson, Haug Partners LLP
  • Emily Wright, Pfizer Inc.

The Publications and Academic Programs Committee advises FDLI staff on how to best attract and engage our academic members and their programs with FDLI; identifies areas for scholarly programming; and provides high-level recommendations for all of FDLI’s publications, including updating essential references and generating content for new book resources. The committee meets approximately quarterly.

  • Paige Samson (Staff Liaison), FDLI
  • Lewis A. Grossman, American University Washington College of Law
  • Joanne Hawana, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
  • Cynthia Schnedar, ELIQUENT Life Sciences
  • Amy Speros, Latham & Watkins LLP

The Update Magazine Peer Review Committee provides manuscript review and editorial feedback of articles submitted for consideration in Update magazine, a virtual, quarterly magazine that reports on analysis and trends in food and drug law. The committee works independently to provide substantive feedback and publication recommendation on the articles.

  • Paige Samson (Staff Liaison), FDLI
  • Lauren Farruggia, Alnylam Pharmaceuticals
  • Jennifer Fulford, toXcel, LLC
  • Stephanie M. Haggerty, Pfizer Inc.
  • Rouget Frederic Henschel, Potomac Law Group
  • Ryan Knox, DePaul University School of Law
  • Chad A. Landmon, Polsinelli PC
  • Melissa B. Runsten, Debevoise & Plimpton, LLP
  • Marc Wagner, BakerHostetler
  • Anna Zhao, AZ Lab Life Sciences Law

Product Area Committees

The Cannabis-Derived Products Committee supports FDLI staff in developing programming in this space. This includes cannabis-specific events, which may occur throughout the year in the form of a webinar, half-day program, or conference, and cannabis-focused content for events covering broader product areas. Responsibilities include identifying key issues and hot topics, developing conference agendas, recommending and recruiting speakers, and promoting programs to colleagues.

  • Lauren Caroline Tadros Potter (Staff Liaison), FDLI
  • Andrew J. Kline (Chair), Perkins Coie LLP
  • Kellsi Booth, Turning Point Brands, Inc.
  • Cheryl Dreyer, Kerry, Inc.
  • Pamela Nicole Epstein, Terpene Belt Processing, LLC
  • William Garvin, Buchanan Ingersoll & Rooney PC
  • Darin Hayakawa, Department of Health – Hawaii
  • Nicholas Markel, Toscano Consulting Group (TCG)
  • Lila McKinley, Connecticut Department of Consumer Protection
  • Deborah Miran, DMiran Consulting
  • Evelina Norwinski, Arnold & Porter LLP
  • Jarred Reiling, DLA Piper LLP (US)
  • Agustin Rodriguez, Troutman Pepper Hamilton Sanders LLP
  • Daniel Charles Rubenstein, Steptoe LLP
  • Frederick A. Stearns, Keller and Heckman LLP
  • Brian Yagi, Johns Hopkins University
  • Zach Zalewski, U.S. Pharmacopeia

The Medical Products Committee supports FDLI staff in developing programming in the medical products space (drugs, devices, and biologics). This includes medical product-specific events, which may occur throughout the year in the form of a webinar, half-day program, or conference, and medical product-focused content for events covering broader product areas. Responsibilities include identifying key issues and hot topics, developing conference agendas, recommending and recruiting speakers, and promoting programs to colleagues.

  • Lauren Caroline Tadros Potter (Staff Liaison), FDLI
  • Sangeeta Abraham, Exponent, Inc.
  • M. Jason Brooke, Brooke & Associates
  • Elizabeth Guo, FDA – OC
  • Ralph F. Hall, University of Minnesota
  • Krista Hessler Carver, Covington & Burling LLP
  • Maarika Kimbrell, Morgan, Lewis & Bockius LLP
  • Brian J. Malkin, TEVA Pharmaceuticals USA, Inc.
  • Jewell Martin, BioMarin Pharmaceutical Inc.
  • Jason Mercer, Facet Life Sciences
  • Son Nguyen, Cooley LLP
  • Joshua M. Oyster, Ropes & Gray LLP
  • Teresa Reguly, Torys LLP
  • Elizabeth Richards, Latham & Watkins LLP
  • Javier Gonzalez Rivera, Arnold & Porter LLP
  • Lance L. Shea, BakerHostetler
  • Nicole Taylor Smith, Philips
  • Eva Temkin, Arnold & Porter LLP
  • James Wabby, AbbVie
  • Krupa Zachariah, Alston & Bird LLP

The Tobacco and Nicotine Products Committee supports FDLI staff in developing programming in this space. This includes both the Tobacco and Nicotine Products Regulation and Policy Conference and Regulatory Science Symposium, both of which typically take place in late October. It also includes any additional tobacco and nicotine product-focused programming, including webinars and panels at events covering broader product areas. Responsibilities include identifying key issues and hot topics, evaluating conference submissions, recommending and recruiting speakers (including keynotes), and promoting the program to colleagues.

  • Paige Samson (Staff Liaison), FDLI
  • Jasjit Ahluwalia, Brown University
  • Maham Akbar, Truth Initiative
  • Aruni Bhatnagar, University of Louisville
  • Shelly Blackwell, EAS Consulting Group
  • Brittani Cushman, Turning Point Brands, Inc.
  • Clifford E. Douglas, Global Action to End Smoking
  • Connor Fuchs, Campaign for Tobacco-Free Kids
  • Joe G. Gitchell, Pinney Associates, Inc.
  • Bryan M. Haynes, Troutman Pepper Hamilton Sanders LLP
  • Eshael Johnson, FDA-CTP
  • Rima Khoury, Fumari, Inc.
  • John L. Marshall, Altria Client Services LLC
  • Daniel P. McGee, Keller and Heckman LLP
  • Brian J. Miller, Johns Hopkins University
  • Gaye Montgomery, Philip Morris International
  • John O’Brien, RAI Service Company (RAISC) (Reynolds American Inc.)
  • Elizabeth Oestreich, ELIQUENT Life Sciences
  • Henry Roemer, Finger, Roemer, Brown & Mariani LLP
  • Sharyn Rutt, Philip Morris International
  • Barry Schaevitz, Fox Rothschild LLP
  • Jim Solyst, JMS Scientific Engagement
  • Mark J. Vaders, Womble Bond Dickinson (US) LLP
  • Jeffrey Weiss, Flagstaff Ventures

Task Forces

The Cosmetics Task Force supports FDLI staff in developing programming in this space. This includes cosmetics-specific events, which may occur throughout the year in the form of a webinar, half-day program, or conference, and cosmetics-focused content for events covering broader product areas. Responsibilities include identifying key issues and hot topics, developing conference agendas, recommending and recruiting speakers, and promoting programs to colleagues. Note that task force members are allowed to simultaneously serve on an FDLI committee.

  • Kelsey Kerr (Staff Liaison), FDLI
  • John Bailey, EAS Consulting Group
  • Kelly Bonner, Duane Morris LLP
  • Cathy L. Burgess, Alston & Bird LLP
  • Mara M. Burr, Consumer Brands Association
  • Robert Durkin, Amin Wasserman Gurnani
  • Daniel R. Dwyer, Kleinfeld, Kaplan & Becker, LLP
  • Jason W. Gordon, Reed Smith LLP
  • Marla Hallacy, Office of Regulatory Affairs, FDA
  • Rouget Frederic Henschel, Potomac Law Group
  • Peter Barton Hutt, Covington & Burling LLP
  • John F. Johnson, Shook, Hardy & Bacon LLP
  • Surya Kundu, Steptoe LLP
  • Jane Massey Licata, Drexel University
  • Srikumaran Melethil, University of Missouri, Kansas City
  • Lisa Navarro, Ramboll US
  • Brandi Reinbold, NSF International
  • Laura Rich, Venable LLP
  • Xin Tao, Baker McKenzie

The Veterinary Products Task Force supports FDLI staff in developing programming in this space. This includes veterinary product-specific events, which may occur throughout the year in the form of a webinar, half-day program, or conference, and veterinary product-focused content for events covering broader product areas. Responsibilities include identifying key issues and hot topics, developing conference agendas, recommending and recruiting speakers, and promoting programs to colleagues. Note that task force members are allowed to simultaneously serve on an FDLI committee.

  • Lauren Caroline Tadros Potter (Staff Liaison), FDLI
  • Elizabeth Butterworth Stutts, Elizabeth Butterworth Stutts, Esq, PLLC
  • Patrick C. Gallagher, PC Gallagher Law P.A.
  • Grace Gowda, Merial, Inc.
  • Karl Nobert, Michael Best & Friedrich LLP
  • Jeannie M. Perron, Covington & Burling LLP

Governance Committees

Audit Committee oversees and evaluates the management’s control over financial reporting. This committee is led by and reports to the FDLI Board of Directors.

*This committee is not seeking applications for 2024

  • Hayley Carpenter (Staff Liaison), FDLI
  • Ricardo Carvajal (Chair), Hyman, Phelps & McNamara, PC
  • Cathy L. Burgess, Alston & Bird LLP
  • Joanne Hawana, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
  • Michael Werner, Holland & Knight LLP
  • Ben Butz (Staff Liaison), FDLI
  • Elizabeth Anderson, FDA – CFSAN
  • Oluwaseun (Kemi) Asante, FDA – CDER
  • Daniel A. Kracov, Arnold & Porter LLP
  • Chadli Pittman, Ropes & Gray LLP
  • Sarah Thompson Schick, Reed Smith LLP
  • John (Barr) Weiner, FDA – OC

Finance Committee oversees FDLI’s financial affairs, including budget formulation and execution, and investment portfolio management. This committee is led by and reports to the FDLI Board of Directors.

  • Hayley Carpenter (Staff Liaison), FDLI
  • Melanie Gross (Chair), Genentech
  • Christina Anderson Mooney, Medtronic
  • Frederick R. Ball, Duane Morris LLP
  • Jeffrey N. Gibbs, Hyman, Phelps & McNamara, PC
  • Elizabeth Oestreich, ELIQUENT Life Sciences